UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.         )

Filed by the Registrant  ☒

Filed by a Party other than the Registrant  ☐

Check the appropriate box:

DBV Technologies S.A.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box)all boxes that apply):

Dear Fellow DBV Shareholders,

Each year, I begin my letter to you with the reminder that DBV Technologies was founded onupon the belief that children with food allergies, their families, and the allergists who treat them, need, and deserve, multiple treatment options. That belief continues to guide our corporate strategy and drives our employees each day as a foundational element of DBV.

Financial diligence and responsible, targeted spending are core components of our culture. We know and appreciate that our shareholders have placed their trust in us, that we will execute with care spending practices appropriate for a late-development stage biotechnology company. In 2022, DBV secured financial support to advance our strategy for Viaskin^™ Peanut. In May, DBV successfully launched an At-The-Market program and subsequently completed sales of new ordinary shares in the form of American Depository Shares (ADSs) for a total gross amount of $15.3 million. In June, DBV announced a $194 million private investment in public equity (PIPE) financing. DBV closed Q2 2022 with a cash balance of $248 million following the ATM and PIPE offerings. We remain committed that this shot in the arm will fuel DBV’s operations through top-line results of our new, Phase 3 Pivotal Study of Viaskin Peanut in 4 – 7 year old children with peanut allergy, VITESSE, anticipated in the first half of 2025.

In June 2022, DBV announced positive topline results from EPITOPE, our Phase 3 Pivotal Study of Viaskin Peanut in toddlers 1 – 3 years old. We shared that 67 percent of subjects treated with Viaskin Peanut 250 µg met response criteria after 12 months, as compared with 33.5 percent of subjects in the placebo arm. The EPITOPE safety results were generally consistent with the safety profile of Viaskin Peanut 250 µg observed in our studies of children ages 4 and older with a confirmed peanut allergy. As patient safety and treatment experience are a priority for DBV, it was encouraging to learn that of the serious adverse events (SAEs) reported, only 1 of the SAEs was deemed related to treatment. Further, of the four subjects in the Viaskin Peanut arm having experienced an anaphylactic reaction determined to be related to, or possibly related to, treatment, 3 resolved with a single dose of epinephrine and 1 resolved without epinephrine. All reported anaphylactic reactions were deemed mild to moderate in severity. In the 12-month treatment period, the trial completion rate was 84.8 percent and was balanced between the Viaskin Peanut and placebo arms. We were also pleased to see that the mean subject compliance to daily patch treatment was above 95 percent in both the active and placebo arms.

The EPITOPE study results were widely shared with the food allergy community with positive reception. DBV also actively engaged in sharing the full EPITOPE trial results at global medical congresses and is currently pursuing publication of the data in a peer-reviewed journal. We know that most peanut-allergic children are diagnosed between 1 – 3 years of age, and yet there are currently no FDA-approved therapies for this age group. The EPITOPE data advanced our understanding of investigational epicutaneous immunotherapy and its ability to induce an immune response with minimal amounts of allergen. We believe that our lead product candidate,these positive findings support the potential clinical benefit of Viaskin Peanut has a profile that is importantin this underserved population and look forward to many families and allergists, and our primary goal is its potential approval inexploring next steps with the United States and European Union.

The first half of 2020 was a challenging time for us as we navigated the U.S. regulatory pathway for Viaskin Peanut. When we began the year in January, the Biologic License Application (BLA) for Viaskin Peanut, which we had submitted and filed in 2019, was under review with the Food and Drug Administration (FDA). On March 16, 2020,

Throughout 2022, DBV worked hard to develop and align with the FDA contacted DBV to inform us that it was cancelling the Advisory Committee for Viaskin Peanut and that, during its ongoing reviewon key elements of the BLA, it had identified questions regarding efficacy, including the impact of patch-site adhesion.

By May 2020, DBV was facing an uncertain regulatory path for Viaskin Peanut and operatingVITESSE protocol, DBV’s Phase 3 Pivotal Study in an industry and world upended by the global COVID-19 pandemic. Although DBV had provided adhesion data tochildren ages 4 – 7 years old with a confirmed peanut allergy. While the FDA to potentially supplementissued a partial clinical hold (PCH) on VITESSE in September 2022, DBV appreciated the Viaskin Peanut BLA, and our FDA target action date of August 5, 2020 remained unchanged, we began to plan for scenarios other than a timely Viaskin Peanut approval. We considered all realistic alternative regulatory scenarios and each one resulted in a significant delay to the transformation of DBV from a clinical-stage biotechnology company to a commercial-stage one with healthy product revenues.

Chief Executive Officer Daniel Tassé recognized that DBV would likely encounter significant financial pressure in the near-term with limited ability to responsibly raise the additional capital necessary for DBV to remain a competitive and viable clinical-stage company. In June, and after several meetings, Daniel and the Board of Directors made the very difficult and necessary decision to reduce the size of DBV and the scope of its operations to maximize the length of time that DBV’s cash could support its operations. On June 26, 2020, DBV initiated a global cost-containment program that included pausing several programs, suspending several activities, shifting selected functions to external business partners, and reducing the workforce. A corporate restructuring is always a difficult and complex process. However, DBV emerged a leaner organization with greater financial flexibility, all critical functions retained, high quality teams, and a cash position that is expected to support DBV operations into the second half of 2022.

On August 3, 2020, DBV received a Complete Response Letterclear feedback from the FDA, regardingwhich specified changes to elements of the BLAVITESSE protocol with the intent for the trial to support a future biologics license application (BLA) submission. The FDA communication contained four protocol modifications: the redefinition of the minimal daily wear time, the addition of a statistical test for the patch adhesion assessment, the reclassification of certain adverse events (AEs) to adverse events of special interest (AESIs) and an increase in the number of trial participants on active treatment. Thankfully, there was no disruption to subjects, as DBV had not yet begun screening or recruitment of subjects into the VITESSE study. Further, the PCH only applied to VITESSE and did not impact any other ongoing DBV clinical studies. While the PCH was a temporary setback, DBV is grateful for the FDA’s additional feedback reflecting careful attention to the VITESSE study and our goal for a path forward.

In December 2022, DBV announced that the FDA had lifted the PCH on the VITESSE Phase 3 Pivotal Study. In lifting the PCH, the FDA confirmed DBV satisfactorily addressed all clinical hold issues identified in the PCH letter. The FDA stated that DBV may proceed with VITESSE with the confirmed revisions to the protocol. Subsequently, DBV submitted the updated protocol to study sites for subsequent Institutional Review Boards (IRB)/Ethics Committees (EC) approval. DBV is currently advancing study forward. We know that the food allergy community is eagerly awaiting the opportunity to study and expand our learnings about the potential of epicutaneous immunotherapy and Viaskin Peanut. The FDA indicatedCompany expects to initiate patient screening in Q1 2023 with the last patient screened in 1H 2024 and topline results anticipated in 1H 2025.

While it could not approve the Viaskin Peanut BLA in its current formis no secret that 2022 contained both highs and identified several issues, including their concern regarding the impact of patch-site adhesion on efficacy. Thelows for DBV, executive management team, supported by a comprehensive working group of internal and external experts, immediately began crafting a plan to address the FDA’s concerns and clarify a clinical and regulatory path forward for Viaskin Peanut in the United States. We submitted the plan to the FDA in the fourth quarter of 2020, and in January 2021, the FDA provided clear guidance on a well-defined path forward for a modified Viaskin Peanut.looking back, I can say with certainty that I am very pleasedproud of our persistence that led to report thatstanding where we are today. DBV continues to make significant progress,rebuilt confidence, strengthened our relationships, and earned our current achievements. Because of our strategic actions in dialogue with the FDA, in advancing the clinical and regulatory development plan for a modified Viaskin Peanut.

I am also pleased to report that the European Medicines Agency (EMA) review of the Marketing Authorization Application (MAA) for Viaskin Peanut is progressing according to our expectations and consistent with our pre-filing exchanges with the EMA. In the fourth quarter of 2020, DBV submitted the MAA, and the EMA confirmed the application was sufficiently complete to begin their review. We expect to provide further updates as the EMA’s review progresses.

Looking ahead to 2021 and beyond, I believe DBV is2022, we are strongly positioned for the future. We remainhave not only progressed the development of our lead product candidate, but also have earlier stage food allergy programs in phase 2 of clinical development for cow’s milk allergy and eosinophilic esophagitis. I am confident that DBV will be well-positioned to bring innovative, specialized therapies to market that help make a meaningful difference to patients worldwide.

Reflecting on the year, 2022 was characterized by perseverance and transformation for DBV. At our core remains the steadfast indedication to science and technology that sets us apart from other biotechnology companies. Those of you who have been a part of our journey for some time know that our commitment to food allergic families is embedded in our corporate culture. We are here to serve our future patients, to give them hope when treatment options have thus far been so limited. We believe that it is unacceptable that avoidance and OIT are the only means of managing a peanut allergy. The curious and courageous minds that compose DBV’s global personnel work hard every day to one day bring Viaskin Peanut to potential approval in the United Statesmarket an innovative and European Union,transformative therapy for children and toddlers living with peanut allergy. Our team will not give up on them. We are looking forward to 2023 as we are driven every day byactively recruiting for the VITESSE Phase 3 Pivotal Study and embarking on possibilities stemming from the results of our foundational belief that children with food allergies, their families,EPITOPE data. Thank you very much for your trust and support as a shareholder—and for being an active contributor to the allergists who treat them, need and deserve multiple treatment options.success of our journey.

Sincerely,

/s/ Michel de Rosen

Michel de Rosen

April 26, 2021

DBV Technologies S.A.

177-181 Avenue Pierre Brossolette

92120 Montrouge France

NOTICE OF ANNUAL COMBINED GENERAL MEETING OF SHAREHOLDERS

To Be Held at 2:10:00 p.m.AM Paris Time on Wednesday, May 19, 2021April 12, 2023

To Shareholders of DBV Technologies S.A.:

The 20212023 Annual Combined General Meeting of Shareholders (the “Annual General Meeting”) of DBV Technologies S.A. (the “Company”), a French société anonyme, will be held on Wednesday, May 19, 2021April 12, 2023, at 2:10:00 p.m.AM Paris time at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette, 92120 Montrouge, France* in closed session without the physical presence of shareholders and other persons entitled to attend in accordance notably with Article 4 of Order No. 2020-321 of March 25, 2020 (as amended and extended by Order No. 2020-1497 of 2 December 2020 and Decree no. 2021-255 of 9 March 2021) to consider the following actions, as more fully described in the accompanying proxy statement:France.

Within the authority of the Ordinary Shareholders’ Meeting:

Within the authority of the Extraordinary Shareholders’ Meeting:

General Meeting as April 21, 2021March 15, 2023 (the “ADS Record Date”). If you wish to have your votes cast at the meeting, you must obtain, complete and timely return at or prior to 10:00 a.m.AM Eastern Time on May 12, 2021April 5, 2023, a voting instruction form from the Depositary, if you are a registered holder of ADSs, or from your broker, bank or other nominee in accordance with any instructions provided therefrom.

We appreciate your continued support of DBV Technologies S.A. and look forward to receiving your vote.

YOUR VOTE IS IMPORTANT. Please read the proxy statement and the accompanying materials. NoWhether or not you expect to attend the meeting, no matter how many Ordinary Shares or ADSs you own, please submit your proxy card or voting instruction form, as applicable, in accordance with the procedures described above.

We appreciate your continued supportImportant Notice Regarding the Availability of DBV Technologies S.A.Proxy Materials for the

Shareholder Meeting to be Held on April 12, 2023:

The proxy statement and look forward to receiving your vote.annual report are available on the Investors section of our website https://www.dbv-technologies.com

* We are monitoring the situation regarding the ongoing COVID-19 pandemic closely and we will monitor the need to potentially alter the date, time or organization of the Annual General Meeting. If we take any additional steps in light of the ongoing COVID-19 pandemic, we will announce the relevant changes in advance by a press release and the filing of additional proxy materials to all ADS holders on or about March 24, 2023. Our registrar, Société Générale Securities Services, will commence mailing the proxy materials to all holders of our Ordinary Shares on or about March 24, 2023, in accordance with French law and requirements.

Along with this proxy statement, we are also providing our 2022 Annual Report on Form 10-K, which includes our financial statements prepared in accordance with U.S. GAAP for the Securities and Exchange Commission. Please monitor our website at https://www.dbv-technologies.com/investor-relations/for updated information and if you intend to view the webcast of the Annual General Meeting, please check the website in advance of the meeting.fiscal year ended December 31, 2022.

TABLE OF CONTENTS

i

ii

ii

DBV Technologies S.A.

177-181 Avenue Pierre Brossolette

92120 Montrouge France

PROXY STATEMENT

FOR THE 20212023 ANNUAL COMBINED GENERAL MEETING OF SHAREHOLDERS

To Be Held at 2:10:00 p.m.AM Paris Time on Wednesday, May 19, 2021April 12, 2023

This proxy statement and the enclosed form of proxy are furnished to holders of Ordinary Shares and ADSs in connection with the solicitation of proxies by our board of directors (the “Board of Directors”) for use at the 20212023 Annual Combined General Meeting of shareholders of DBV Technologies S.A. (the “Company”), a French société anonyme, and any postponements, adjournments or continuations thereof (the “Annual General Meeting”). The Annual General Meeting will be held on Wednesday, May 19, 2021April 12, 2023, at 2:10:00 p.m.AM Paris time at 177-181 Avenue Pierre Brossolette, 92120 Montrouge, France. In accordance notably with Article 4 of Order No. 2020-321 of 25 March 2020 adapting the rules for meetings and deliberations of meetings and governing bodies of legal persons and entities without legal personality under private law due to the COVID-19 pandemic, as amended and extended, among others, by notably Order No. 2020-1497 of 2 December 2020 extending and amending Order No. 2020-321 of 25 March 2020, and by Decree no. 2021-255 of 9 March 2021 extending the period of application of Order No. 2020-321 of 25 March 2020, Decree no. 2020-418 of 10On April 2020 and Decree no. 2020-629 of 25 May 2020, the Annual General Meeting will be held in closed session without the physical presence of shareholders and other persons entitled to attend. On May 19, 2021,12, 2023, starting at 2:10:00 p.m.AM Paris time, the Annual General Meeting will be webcast with live audio on our website https://www.dbv-technologies.com/fr/www.dbv-technologies.com. in the Events and Presentations section. Shareholders will also be able to access the recorded webcast of the Annual General Meeting on the Company’s website for two years following the date of the Annual General Meeting. The inclusion of our website address here and elsewhere in this proxy statement does not include or incorporate by reference the information on our website into this proxy statement.

If we take any additional steps in light of the COVID-19 pandemic, we will announce the relevant changes in advance by a press release and the filing of additional proxy materials with the Securities and Exchange Commission (“SEC”). Please monitor the Investor section of our website at https://https://www.dbv-technologies.com/investor-relations/ for updated information and if you intend to view the webcast of the meeting, please check the website in advance of the meeting. In this proxy statement references to “DBV,” “the company,” “our company,” “we,” “us” and “our” refer to DBV Technologies S.A. and our consolidated subsidiaries.

Important Notice Regarding the Availability of Proxy Materials for the

Shareholder Meeting to be Held on May 19, 2021:

The proxy statement and annual report are available at: https://www.dbv-technologies.com/investor-relations/financial-information/annual-reports/

You may also request paper copies of materials by contacting:

DBV Technologies S.A.

177-181 avenue Pierre Brossolette

92120 Montrouge, France

Attention: Legal Department

Email: investors@dbv-technologies.com

Citibank, N.A., as the depositary (the “Depositary”), or a broker, bank or other nominee, will provide the proxy materials to holders of American Depositary Shares, each representing one-half of one Ordinary Share (“ADSs”). We expect the Depositary will mail the proxy materials to ADS holders on or about April 28, 2021. Our registrar, Société Générale Securities Services, will commence mailing of proxy materials to all holders of our ordinary shares, nominal value €0.10 per shares (“Ordinary Shares”), on or about May 3, 2021, in accordance with French law and requirements.

IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING

The information provided in the “question and answer” format below is for your convenience only and is merely a summary of the information contained in this proxy statement. You should read this entire proxy statement carefully. Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference into this proxy statement and references to our website address in this proxy statement are inactive textual references only.

What matters will be voted at the Annual General Meeting?

There are 3841 proposed resolutions (the “Proposals”) scheduled to be considered and voted on at the Annual General Meeting:

Within the authority of the Ordinary Shareholders’ Meeting:

Within the authority of the Extraordinary Shareholders’ Meeting:

Within the authority of the Ordinary Shareholders’ Meeting:

What does a DBV ADS represent?

Each ADS represents one-half of one Ordinary Share of DBV Technologies S.A. Each Ordinary Share is entitled to one vote.

As of February 15, 2023, 94,137,145 Ordinary Shares were outstanding, of which 23,806,124 were represented by ADSs.

What if another matter is properly brought before the meeting?

At this time, the boardBoard of directorsDirectors is unaware of any matters to be presented at the Annual General Meeting, other than as set forth above and the possible additional shareholder resolutions that may properly be submitted before the Annual General Meeting in accordance with applicable French law.

Holders of Ordinary Shares: To address the possibility of another matter being presented at the Annual General Meeting, holders of Ordinary Shares may use their proxy card to (i) abstain from voting on such matters, (ii) vote “AGAINST” on such matters, or (iii) grant a proxy to the chairman of the Annual General Meeting to vote on any new matters that are proposed during the meeting, or (iv) grant a voting proxy to another shareholder, yourtheir spouse, or yourtheir partner with whom youthey have entered into a civil union. If no instructions are given with respect to matters about which we are currently unaware, yourholder’s Ordinary Shares will not be voted on such matters.

If a holder of Ordinary Shares chooses to grant a proxy to the chairman of the Annual General Meeting, with respect to either all matters or only any additional matters not disclosed in this proxy statement, the chairman of the Annual General Meeting shall issue a vote in favor of adopting such undisclosed resolutions submitted or approved by the boardBoard of directorsDirectors and a vote against adopting any other such undisclosed resolutions.

Holders of ADSs: Ordinary Shares underlying ADSs will not be voted on any matter not disclosed in the proxy statement.

Why is the Company soliciting my proxy?

Our boardBoard of directorsDirectors is soliciting your proxy to vote at the 20212023 annual meeting of shareholders to be held at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France, on Wednesday, May 19, 2021,April 12, 2023, at 2:10:00 p.m.AM Paris time in closed session without the physical presence of the

As an ADS holder, you will not be entitled to vote in person at the Annual General Meeting. To the extent you provide the Depositary or your broker, bank or other nominee, as applicable, with voting instructions, the Depositary will, to the extent practicable and subject to French law and the terms of the deposit agreement, vote the Ordinary Shares underlying your ADSs in accordance with your instructions.

How many votes do I have?

Each share of our ordinary sharesOrdinary Shares that you own entitles you to one vote. Each American Depositary ShareADS represents one-half of one ordinary share.Ordinary Share. Voting instructions with respect to ADSs may be given only in respect of a number of ADSs representing an integral number of ordinary shares.Ordinary Shares.

How will my Ordinary Shares be voted if I grant my proxy to the chairman of the Annual General Meeting?

If you are a holder of Ordinary Shares and you grant your proxy to the chairman of the Annual General Meeting, the chairman of the Annual General Meeting will vote your Ordinary Shares in accordance with the boardBoard of directors’Directors’ recommendations. As a result, your Ordinary Shares would be voted “FOR” the nominees of the boardBoard of directorsDirectors in Proposal Nos. 6 to 109 and “FOR” each of Proposal Nos. 1 to 5 11and 10 to 15, and 18 to 38 and “AGAINST” each of Proposal Nos. 16 and 17.41.

How many votes are needed for approval of each proposed resolution?

Only holders of bearer shares whose account-holding institution has subscribed to the Votaccess system and offers them this service for this general meeting will be able to access it. The securities account holder of the

address: assemblees.generales@sgss.socgen.com.assemblees.generales@sgss.socgen.com. The form must bear the surname, first name and address of the person being named as proxy, the words “In the capacity of proxy”, and must be dated and signed. The direction of the vote must be indicated in the “I vote by mail” box of the form. The proxy must attach a copy of his or her identity card and, if applicable, a power of attorney from the legal entity he/she represents. To be taken into account, the electronic message must be received by Société Générale no later than the fourth day prior to the date of the meeting, which is Saturday, May 15, 2021.

In accordance with the provisions of Article R. 225-79 of the French Commercial Code, notification of the appointment and revocation of a proxy to the Chairman may also be made in the following manner:

necessary to meet legal requirements. We will, however, forward to management any written comments you make on the proxy card or that you otherwise provide.

Where can I find the voting results of the Annual General Meeting?

The preliminary voting results will be announced at the annual meeting, and we will publish preliminary results, or final results if available, in a Current Report on Form 8-K within four business days of the annual meeting. If final results are unavailable at the time we file the Form 8-K, then we will file an amended Current Report on Form 8-K to disclose the final voting results within four business days after the final voting results are known. 

What Are the Costs of Soliciting These Proxies?

We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone, fax or email. We will pay these employees and directors no additional compensation for

your broker believe that the ADS holders of record are members of the same family. This practice, referred to as “householding,” benefits both you and us. It reduces the volume of duplicate information received at your household and helps to reduce our expenses. The rule applies to our annual reports, proxy statements and information statements. Once you receive notice from your broker or from us that communications to your address will be “householded,” the practice will continue until you are otherwise notified or until you revoke your consent to the practice. ADS holders who participate in householding will continue to have access to and utilize separate proxy voting instructions.

If a broker or other nominee holds your ADSs and (1) your household received a single set of proxy materials this year, but you would prefer to receive your own copy or you do not wish to participate in householding and would like to receive your own set of our proxy materials in future years or (2) you share an address with another ADS holder and together both of you would like to receive only a single set of proxy materials, please contact the broker or other nominee directly and inform them of your request. Be sure to include your name, the name of your brokerage firm and your account number.

Can I receive Company shareholder communications by electronic delivery?

Most shareholders can elect to view or receive copies of future proxy materials over the Internet instead of receiving paper copies in the mail. You can choose this option and save us the cost of producing and mailing these documents by following the instructions provided on your proxy card or by following the instructions provided when you vote over the Internet.

Where can I find documents referenced in this proxy statement?

An English translation of the full text of the resolutions to be submitted to shareholders at the Annual General Meeting is included in Annex A of this proxy statement and this proxy statement will be accompanied

of directorsDirectors at the address below no later than December 29, 2021.November 27, 2023. Only those resolutions that comply with the requirements of Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), will be included in the Company’s proxy statement for the 20222023 Annual General Meeting of shareholders.

In addition, under French law, holders of Ordinary Shares are permitted to submit a resolution for consideration so long as such matter is received by the Company no later than 25 days prior to the date of the meeting. Holders of Ordinary Shares wishing to present resolutions at the 20222023 Annual General Meeting of shareholders made outside of Rule 14a-8 under the Exchange Act must comply with the procedures specified under French law. A shareholder who meets the requirements set forth in Articles L. 225-105 and R. 225-71 of the French Commercial Code may submit a resolution by sending such resolution to the address below by registered letter with acknowledgment of receipt or via e-mail. The resolution must include the text of the proposed resolution, a brief explanation of the reason for such resolution and an affidavit to evidence the shareholder’s holdings. Any holder of Ordinary Shares who meets the requirements set forth in Articles L. 225-105 and R. 225-71 of the French Commercial Code also may submit a director nomination to be considered by the nomination and corporate governance committee for nomination by following the same process outlined above and including the information regarding the director as set forth in Article R. 225-83 5^o of the French Commercial Code in their submission.

In addition to satisfying the requirements under French law and our by-laws, to comply with the universal proxy rules, any holder of ADSs and/or Ordinary Shares who intends to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than February 12, 2024.

All submissions to the Company should be made to:

DBV Technologies S.A.

177-181 avenue Pierre Brossolette

92120 Montrouge, France

Attention: Legal Department

Email: investors@dbv-technologies.comlegal@dbv-technologies.com

BOARD OF DIRECTORS AND CORPORATE GOVERNANCE

Board of Directors

Our business affairs are managed under the direction of our boardBoard of directors,Directors, which is currently composed of nineten members. SevenNine of our directors are independent within the meaning of the listing standards of the Nasdaq Stock Market.Market (“Nasdaq”).

The following table sets forth the names, ages as of April 21, 2021,March 24, 2023, and certain other information for each of the nominees for director each of the provisionally appointed directors subject to shareholder ratification, and for each of the continuing members of our boardBoard of directors:Directors:

Nominees for Director:

Daniel TasséTassé has served as Chief Executive Officer since November 2018 and as a member of our Board of Directors since March 2019. Mr. Tassé has served on the board of directors of Regenxbio Inc., a U.S. publicly traded biotechnology company, since March 2019.2016 and currently is Chair of Regenxbio Inc.’s compensation committee. From 2013 to 2021, Mr. Tassé served on the board of directors of Indivior plc, a British (London Stock Exchange) publicly traded specialty pharmaceutical company. While on the board of Indivior, Mr. Tassé has served as Lead Independent Director, Interim Chair and Chair of the Audit Committee. From 2018 to 2019, Mr. Tassé served on the board of directors of HLS Therapeutics, a Canadian publicly traded pharmaceutical company. From 2014 to 2019, Mr. Tassé served on the board of directors of Bellerophon Therapeutics, Inc., a U.S. publicly traded biotherapeutics company. From March 2016 to November 2018, Mr. Tassé served as the Chairman and Chief Executive Officer of Alcresta Therapeutics, Inc., a U.S. pediatric-focused rare disease biotechnology company. From January 2008 to April 2015, Mr. Tassé served as the Chairman and Chief Executive Officer of Ikaria, Inc., whicha U.S. company that develops drugs and devices for critically ill patients. In April 2015, Ikaria, Inc. was acquired by Mallinckrodt Pharmaceuticals. Mr. Tassé holds a B.Sc. in Biochemistry from Université de Montréal. Mr. Tassé is fluent in French and English. The boardBoard of directorsDirectors believes that Mr. Tassé’s leadership and extensive experience in the pharmaceutical industry will allow him to drive us to the success of our objectives.

Michel de Rosen has served as a member of our board of directors since May 2018 and as Non-Executive Chairman of our board of directors since March 2019. Mr. de Rosen also serves on the board of directors of Faurecia and Pharnext. Mr. de Rosen served as Chairman and Chief Executive Officer of Eutelsat from 2009 until his retirement in November 2017, Chairman and Chief Executive Officer of ViroPharma from 2000 to 2008, and Chairman and Chief Executive Officer of Rhone-Poulenc Santé from 1993 to 1999. He has also held numerous positions at the French Ministries of Finance, Defense, Industry and Telecommunication. Mr. de Rosen holds an M.B.A. from HEC and an M.B.A. from Ecole Nationale d’Administration. The board of directors

believes that Mr. de Rosen’s extensive business experience in the biopharmaceutical industry and over 15 years’ experience in the United States will be instrumental to the success of our objectives.

Dr. Torbjörn Bjerke has served as a member of our board of directors since 2006. Dr. Bjerke has served as the portfolio manager of Arctic Aurora LifeScience since January 2016 and as a director of TXP Pharma GmbH since 2014 and SynAct Pharma since April 2016. He previously served as the Chief Executive Officer of Karolinska Development AB from 2011 to 2014. Prior to then, Dr. Bjerke was the President and Chief Executive Officer of Orexo AB, a position he held from 2007 until January 2011, President and Chief Executive Officer of Biolipox AB and Director of Pharmacology at AstraZeneca. Dr. Bjerke holds a Ph.D. in Medicine from Aarhus Universitet. The board of directors believes that Dr. Bjerke’s experience in the pharmaceutical industry, particularly his extensive experience in allergy treatment field, and his years of business and leadership experience allow him to make valuable contributions to the board of directors. Dr. Bjerke’s term as a director will terminate immediately following the Annual Meeting.

Maïlys Ferrère has served as a member of our boardBoard of directorsDirectors since June 2016 and previously served as a non-voting observer of our boardBoard of directorsDirectors since our initial public offering on Euronext Paris in March 2012. Ms. Ferrère has served as a Director, Head of the Large Venture Investment Activity at Bpifrance, France’s public investment bank, since October 2013 and is affiliated with one of our significant shareholders. Ms. Ferrère serves as chief executive officer of Cornovum S.A and Three4Tech. Ms. Ferrère serves on the board of directors of Sequans Communications S.A., a publicly traded French designer, developer and supplier of cellular semiconductor solutions, Valnveva SE, a publicly traded company listed on Eurnoext Paris and Nasdaq, Devialet, an unlisted company, and Doctolib an unlisted company. Ms. Ferrère served on the board of directors of Innate Pharma S.A., a French global oncology-focused biotech company, from 2017 to 2021. Ms. Ferrère served on the board of directors at Valneva S.A., a publicly traded French biotech company, from 2016 and 2019. Ms. Ferrère served on the board of directors at Gensight Biologics S.A., a French publicly traded biotechnology company, from 2016 to 2019. Ms. Ferrère served on the board of directors of Pixium Vision S.A., a French publicly traded bioelectronics and brain machine interface technology company, from 2015 to 2017. She graduated from Institut d’Etudes Politiques Paris, and began her career with the General Inspectorate of Société Générale before working for multiple French banks in the equity capital markets origination department. The boardBoard of directorsDirectors believes that Ms. Ferrère’s experience in the banking industry and her knowledge of capital markets allow her to make valuable contributions to the boardBoard of directors.Directors.

Michael J. Goller has served as a member of our boardBoard of directorsDirectors since October 2015. Mr. Goller serves asis a Partner of Baker Brothers Investments,Bros. Advisors LP, a fund management company focused on long-term investments in life-sciences companies. Prior to joining Baker Brothers in 2005, Mr. Goller was an associateAssociate of JPMorgan Partners, LLC, a private equity division of JPMorgan Chase & Co., where he focused on venture investments in the life sciences sector from 1999 to 2003. Mr. Goller began his career as an investment banker with Merrill Lynch and Co., an investment bank, from 1997 to 1999. Mr. Goller serves on the board of directors of BeiGene, Ltd., a Chinese publicly traded biotechnology company. Mr. Goller served on the board of directors of Levo Therapeutics, a biotechnology company, from August 2017 to February 2019. Mr. Goller holds a B.S. in Molecular and Cell Biology from The Pennsylvania State University, and a MastersMaster’s in both Biotechnology at the School of Engineered and Applied Sciences and Business Administration fromat the Wharton School at the University of Pennsylvania. The boardBoard of directorsDirectors believes that Mr. Goller’s experience in the life sciences industry and his knowledge of corporate development matters allow him to make valuable contributions to the boardBoard of directors.Directors.

Viviane MongesDaniele Guyot-Caparros has served as a member of our Board of Directors since October 2022. Ms. Guyot-Caparros has a longstanding track record in finance and business operations. She began her career in audit and corporate finance with PricewaterhouseCoopers (PwC) until 1992 and later joined Rhône-Poulenc-Rorer from 1992 until 2009 (later Aventis and Sanofi) where she held several senior finance positions including Chief Financial Officer Global Research and Development and Chief Financial Officer Europe, Group Planning. Ms. Guyot-Caparros also held responsibilities in business development, pricing, and portfolio management. In 2008, Ms. Guyot-Caparros became Senior Advisor for Deloitte France to support the development of the Life Sciences and Health Care Industry practice. Ms. Guyot-Caparros has held independent director responsibilities in several biotechnology and medical technology companies. From 2015 to 2017 she was a member of the supervisory board and the audit committee of directors since MayDiaxonhit (which became Eurobio Scientific, listed on Euronext Growth). She chaired the audit committee of Supersonic Imagine until its acquisition by the Hologic, a U.S. publicly traded company, in 2019. From 2013 to June 2022, Ms. Monges also servesGuyot-Caparros served on the board of directors of Novo Holdings, Chimique Belge (UCB), Idorsia PharmaceuticalsONXEO (listed on Euronext, OMS Copenhagen and Voluntis.then Euronext Growth) she chaired the audit committee and also chaired the board from May 2019 to July 2021. Ms. Monges has served asGuyot-Caparros is a strategic advisor to NeoMedLight since January 2014. Ms. Monges served as Vice Presidentgraduate of Finance & Control – Nestlé Business Excellence at Nestlé S.A. from February 2015 to May 2017, Group Chief Financial Officer at Nestlé Skin Health from October 2010 to February 2015Institut Commercial de Nancy, specializing in finance and Global Chief Financial Officer – OTC Division at Novartis from June 2008 to September 2010. Ms. Monges received an M.B.A. from ESCP Business School.accounting. The boardBoard of directorsDirectors believes that Ms. Monges’ extensive businessGuyot-Caparros’ profound experience in the biopharmaceutical industry allowscorporate finance will allow her to make valuable contributions to the boardBoard of directors.

Timothy E. Morrishas served as a member of our board of directors since March 2021. Mr. Morris has served as the Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. since August 2020. He previously served as the Chief Financial Officer of Iovance Biotherapeutics, Inc. from August 2017 to June 2020 and as the Chief Financial Officer and Head of Business Development of AcelRx Pharmaceuticals, Inc. from March 2014 to June 2017. Mr. Morris previously served as a member of the board of directors of Humanigen, Inc. from June 2016 to August 2020. Mr. Morris received his BS in Business with an emphasis in Accounting from California State University, Chico, and is a Certified Public Accountant (Inactive). The board of directors believes that Mr. Morris’ extensive operational experience with public companies in the biopharmaceutical industry, particularly in the areas of finance and corporate development, allows him to make valuable contributions to the board of directors.Directors.

Continuing Directors:

Adora Ndu ishas served as a nominee formember of our boardBoard of directors.Directors since May 2021. Dr. Ndu has served as the Chief Regulatory Affairs Officer of BridgeBio Pharma Inc., a publicly traded U.S. biotechnology company, since January 2022, and its Chief Regulatory and Interim Legal Officer since September 2022. From January 2021 to January 2022, Dr. Ndu served as the Group Vice President and Head of Worldwide Research & Development, Strategy, Scientific Collaborations and Policy at BioMarin Pharmaceutical, Inc. since January 2021.(“BioMarin”), a publicly traded U.S. biotechnology company. She previously served in positions of increasing responsibility at BioMarin, as the Vice President, Regulatory Affairs, Policy, Research, Engagement & International from August 2019 to January 2021, Executive Director from September 2017 to July 2019 and Senior Director from February 2017 to September 2019. Prior to joining BioMarin, Dr. Ndu was an adjunct faculty member at the University of Maryland University College from 2016 to 2019 and served in various roles at the U.S. Food and Drug Administration from 2008 to 2016, most recently as a Division Director in the Division of Medical Policy Development. Dr. Ndu has served as an adjunct lecturer with the Johns Hopkins University Masters in Biotechnology Enterprise and Entrepreneurship program since 2019. Dr. Ndu received a Doctor of Pharmacy from Howard University and a Juris Doctor from the University of Maryland Francis King Carey School of Law. Dr. Ndu serves on the Board of Directors of Acadia Pharmaceuticals. The boardBoard of directorsDirectors believes that Dr. Ndu’s extensive experience in the biopharmaceutical industry will allowallows her to make valuable contributions to the boardBoard of directors.Directors.

Julie O’Neill has served as a member of our boardBoard of directorsDirectors since June 2017. From January 2015 to September 2018, Ms. O’Neill was served as the Executive Vice President, Global Operations for Alexion Pharmaceuticals Inc. (“Alexion”), a U.S. pharmaceutical subsidiary of AstraZenica. From 2014 to 2015, Ms. O’Neill was Senior Vice President of Global Manufacturing Operations and General Manager of Alexion Pharma International Trading.Trading, a subsidiary of Alexion. Prior to joining Alexion, Ms. O’Neill served in various leadership positions at Gilead Sciences, Inc., a U.S. publicly traded biopharmaceutical company, from 1997 to 2014 including Vice President of Operations and General Manager of Ireland from 2011 to 2014. Prior to Gilead Sciences, Ms. O’Neill held leadership positions at Burnil Pharmacies and Helsinn Birex Pharmaceuticals.Pharmaceuticals, Inc., an Irish pharmaceutical company. She is the Chairperson for the National Standards Authority of Ireland and is a member of the Boardsboards of the National Institute for Bioprocessing Research & Training, ICON plc, an Irish publicly traded clinical research organization, Hookipa Pharma Inc., a U.S. publicly traded biotechnology company, Achilles Therapeutics plc, a British publicly traded biotechnology company, ILC Dover, LP, a U.S. engineering development and the American Chamber of Commerce, Ireland.manufacturing company, and Angus Chemical Company, a U.S. global specialty and fine chemical company. From January 2019 to October 2019, Ms. O’Neill was engaged by us to serve as a consultant to support CMC activities, including our BLA resubmission for ViaskinTMViaskin^TM Peanut. Ms. O’Neill received a Bachelor of Science in Pharmacy from University of Dublin, Trinity College and a Masters of Business Administration from University College Dublin (SmurfitSmurfit School of Business).Business. The boardBoard of directorsDirectors believes that Ms. O’Neill’s experience in the life sciences industry and her knowledge of corporate development matters allow her to make valuable contributions to the boardBoard of directors.Directors.

Ravi M. Rao hasserved as a member of our Board of Directors since May 2021. Dr. Rao also serves as the Chief Medical Officer both at Oxford Biomedica since March 2022 and at Sitryx Therapeutics since April 2022 and is a nominee for our boardVenture Partner at SV Health Investors. He previously served as Head of directors. He has servedR&D at Swedish Orphan Biovitrum and also as the Chief Medical Officer of Swedish Orphan Biovitrum AB, a global biopharmaceutical specialty company, sincefrom August 2020.2020 to January 2022. From October 2019 to August 2020, Dr. Rao served as Chief Medical Officer of Aeglea Biotherapeutics Inc., a clincal-stageU.S. publicly traded clinical-stage company developing enzyme therapies for rare metabolic disease. Prior to that, from 2012 to October 2019, Dr. Rao was a Vice President at GlaxoSmithKline plc, a publicly traded British multinational pharmaceutical company. Dr. Rao received a Bachelor of Arts with Honors from the University of Cambridge, Gonville and Caius College; an MB.BChir from the University of Cambridge; a MRCP from the Royal College of Physicians, London; a CCST in Rheumatology from the General Medical Council; and a Ph.D. from Imperial College London. The boardBoard of directorsDirectors believes that Dr. Rao’s experience in clinical development and medical affairs will allowallows him to make valuable contributions to the Board of Directors.

Michel de Rosen has served as a member of our Board of Directors since May 2018 and as Non-Executive Chairman of our Board of Directors since March 2019. Mr. de Rosen also serves on the board of directors.directors of Faurecia SE, a publicly traded French global automotive supplier since 2017, and served on the board of directors of Pharnext SA, a publicly traded French biopharmaceutical company from 2015 until 2022. Mr. de Rosen previously served on the board of directors of Idorsia Pharmaceuticals Ltd., a publicly traded Swiss biopharmaceutical company, from 2020 to 2021. Mr. de Rosen served as Chairman and Chief Executive Officer of Eutelsat, a publicly traded French satellite operator, from 2009 until his retirement in November 2017, Chairman and Chief Executive Officer of ViroPharma Incorporated, a U.S. biopharmaceutical company that was publicly traded prior to its acquisition by Shire plc, from 2000 to 2008, and Chairman and Chief Executive Officer of Rhone-Poulenc Santé, a French chemical and pharmaceutical company, from 1993 to 1999. He has also held numerous positions at the French Ministries of Finance, Defense, Industry and Telecommunication. Mr. de Rosen holds an M.B.A. from HEC and an M.B.A. from Ecole Nationale d’Administration. The Board of Directors believes that Mr. de Rosen’s extensive business experience in the biopharmaceutical industry and over 15 years’ experience in the United States will be instrumental to the success of our objectives.

Timothy E. Morrishas served as a member of our Board of Directors since March 2021. Mr. Morris has served as Chief Finance Officer of Opthea Limited since October 2022. Previously he served as Chief Operating Officer and Chief Financial Officer of Humanigen, Inc., a publicly traded U.S. biopharmaceutical company, since August 2020. He previously served as the Chief Financial Officer of Iovance Biotherapeutics, Inc., a publicly traded U.S. biopharmaceutical company, from August 2017 to June 2020, and as the Chief Financial Officer and Head of Business Development of AcelRx Pharmaceuticals, Inc., a publicly traded U.S. specialty pharmaceutical company, from March 2014 to June 2017. Mr. Morris serves on the board of directors of Aquestive Therapeutics, Inc. (NASDAQ: AQST), Univercells SA, a Belgian biomanufacturing company since August 2022, and Humanetics Corporation, a U.S. pharmaceutical company since October 2022, and he previously served as a member of the board of directors of Humanigen, Inc. from June 2016 to August 2020. Mr. Morris is the sole member of Aacolade Pharma LLC. Mr. Morris received his BS in Business with an emphasis in Accounting from California State University, Chico, and is a Certified Public Accountant (Inactive). The Board of Directors believes that Mr. Morris’ extensive operational experience with public companies in the biopharmaceutical industry, particularly in the areas of finance and corporate development, allows him to make valuable contributions to the Board of Directors.

Daniel B. Soland has served as a member of our boardBoard of directorsDirectors since March 2015. Mr. Soland most recentlypreviously served as Senior Vice President and Chief Operating Officer of ViropharmaIdera Pharmaceuticals, Inc., a publicly traded U.S. biopharmaceutical company, from January 2021 until October 2022. Mr. Soland also served as Senior Vice President and Chief Operating Officer of ViroPharma Incorporated, a U.S. biopharmaceutical company that was publicly traded prior to its acquisition by Shire plc, from March 2008 to December 2014, and currently serves on the board of directors of Acadia Pharmaceuticals Inc., a publicly traded U.S. biopharmaceutical company, since 2015 and previously on the board of directors of Kalvista Pharmaceuticals, Inc., a publicly traded U.S. pharmaceutical company from 2019 to 2022. In addition to his role at Viropharma,ViroPharma Incorporated, where he helped build the organizational and commercial infrastructure that resulted in an 11-fold increase in Viropharma’sViroPharma Incorporated’s share price during his tenure, Mr. Soland previously served as President of Chiron Vaccines, a pharmaceutical company, from 2005 to 2006 and helped engineer a turnaround that contributed to Chiron’s acquisition by Novartis. Prior to then, he served as President and Chief Executive Officer of Epigenesis Pharmaceuticals.EpiGenesis Pharmaceuticals from 2002 to 2005. At GlaxoSmithKline Biologicals, a subsidiary of GlaxoSmithKline plc, a British global healthcare company, Mr. Soland served as Vice President and Director, Worldwide Marketing Operations.Operations from 1993 to 2002. Earlier in his career, Mr. Soland held positions of increasing responsibility in sales and product management at Pasteur-Merieux’s Connaught Laboratories. He holds a B.S. in Pharmacy from the University of Iowa. The boardBoard of directorsDirectors believes that Mr. Soland’s extensive executive and management

There are no family relationships between or among any of our continuing directors, provisionally appointed directors or director nominees. The principal occupation and employment during the past five years of each of our directors and nominee was carried on, in each case except as specifically identified above, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or understanding between any of our directors or nominee and any other person or persons pursuant to which he or she is to be selected as a director or nominee.

There are no legal proceedings to which any of our directors is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or any of our subsidiaries.

Board Diversity

The diversity of our Board under Nasdaq rules is listed below.

Director Compensation

On December 9, 2016, upon recommendation of our compensation committee, our board of directors approved an amendment to our non-executive director compensation policy to set attendance fees for our non-employee directors at a fixed annual retainer of €70,000 per year, regardless of whether or not the director is independent. Under the policy, the chairman of the audit committee will be entitled to an additional retainer of €20,000 per year, the chairman of the compensation committee will be entitled to an additional retainer of €10,000 per year, and the other members of our audit committee and compensation committee, regardless of whether or not the director is independent, will each be entitled to an additional retainer of €5,000 per year.

On June 15, 2017,May 19, 2021, our shareholders at our ordinary shareholders’ general meeting (the “General Meeting of May 19, 2021”) set the total annual attendance fees to be distributed among non-employee directors at €600,000,€800,000, which is then distributed according to the amended non-executive director compensation policy. Shareholder authorization for total attendance fees is automatically renewed each year, unless otherwise decided by our shareholders at an ordinary shareholders’ general meeting. See Proposal 11.9 of the General Meeting of May 12, 2022.

On December 20, 2022, upon recommendation of our Compensation Committee, our Board of Directors decided to allocate the non-executive directors’ compensation for 2022 as follows:

which representrepresents respectively the average exchange rate for the year ended December 31, 20202022, and the exchange rates on the datedates of payment. Mr. Tassé, our Chief Executive Officer, and Ms. FerréFerrère, a representative of BPI France, are each directors, but do not receive any additional compensation for their services as a director. Ms. Giraut resigned from our board of directors effective March 22, 2021, and Dr. Bjerke’s service as a director will terminate immediately following the Annual General Meeting.directors.

The following table sets forth information regarding the aggregate number of non-employee warrant awards held by our non-employee directors as of December 31, 2020.2022. None of our non-employee directors were granted warrants during the financial year ended December 31, 2020. None of our non-employee directors held other stock awards or options as of December 31, 2020.2022.

Corporate Governance

Board Independence

As required under the Nasdaq listing standards, a majority of the members of a listed company’s Board must qualify as “independent,” as affirmatively determined by the Board. The Board consults with our counsel to ensure that the Board’s determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.

Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and us, our senior management and our independent auditors, the Board has affirmatively determined all of our directors, other than Mr. Tassé and Ms. O’Neill,, are

Board Meetings and Committees

During our fiscal year ended December 31, 2020,2022, the boardBoard of directorsDirectors held 1813 meetings (including regularly scheduled and special meetings), and each director attended at least 75% of the aggregate of (i) the total number of meetings of our boardBoard of directorsDirectors held during the period for which he or she has been a director and (ii) the total number of meetings held by all committees of our boardBoard of directorsDirectors on which he or she served during the periods that he or she served as required under the charter of our boardBoard of directors.Directors.

Below is a description of each committee of the Board.

Except for renewal, the recommendation must be justified and contain at least two choices while stating a reasoned preference. This recommendation is prepared following a selection procedure led by our audit committee.Audit Committee. The recommendations and preferences of our audit committeeAudit Committee are presented at our general meeting held to determine the appointment of the statutory auditor;

Our audit committeeAudit Committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of the Nasdaq Stock Market.Nasdaq. A copy of the charter of our audit committeeAudit Committee is available onin the Corporate Governance section of our website at https://dbv-technologies.comwww.dbv-technologies.com. During our fiscal year ended December 31, 2020,2022, our audit committeeAudit Committee held 126 meetings.

Nasdaq rules require that the audit committeeAudit Committee have the specific audit committeeAudit Committee responsibilities and authority necessary to comply with Rule 10A-3(b)(2), (3), (4) and (5) under the Exchange Act, which requires, among other things, that the audit committeeAudit Committee have direct responsibility for the appointment, compensation, retention and oversight of our auditors. However, Rule 10A-3 provides that if the laws of a company’s home country prohibit the full board of directors from delegating such responsibilities to the audit committee,Audit Committee, the audit committee’sAudit Committee’s powers with respect to such matters may instead be advisory. As indicated above, under French law, our audit committeeAudit Committee may only have an advisory role on matters requiring approval of the boardBoard of directorsDirectors under French law and can only make recommendations to our boardBoard of directorsDirectors on such matters. Moreover,

Nominating and Corporate Governance Committee. The principal responsibilities of our nominating and governance committee include (i) preparing proposals for the renewal, replacement or appointment of new directors, in consultation with the Chairman of our boardBoard of directors,Directors, (ii) providing an opinion, with the support of the Chairman of our boardBoard of directors,Directors, on the appointment or replacement of the Chief Executive Officer and/or the Executive Vice Presidents, as the case may be, as well as the members of the Executive Committee and (iii) establishing, when appropriate, with the agreement of the Chairman of our boardBoard of directors,Directors, a succession plan for executive corporate officers. Dr. Bjerke, Ms. Ferrère, Mr. Goller, Mr. Rao, and Messrs. Goller andMr. de Rosen currently serve on the nominating and governance committee.Nominating Committee. Ms. Goller is the chairperson of this committee. Dr. Bjerke will cease service on the Nominating and Corporate Governance Committee upon the termination of his service as a director immediately following the Annual General Meeting.Committee.

Our nominating and corporate governance committeeNominating Committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of the Nasdaq Stock Market.Nasdaq. A copy of the

questions in writing to the chairmanChairman of our boardBoard of directorsDirectors 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France. Communications will be distributed to our boardBoard of directors,Directors, or to any individual director or directors as appropriate, depending on the

REPORT OF AUDIT COMMITTEE

The audit committeeAudit Committee of our boardBoard of directors,Directors, which consists entirely of directors who meet the independence and experience requirements of the Nasdaq, Stock Market, has furnished the following report:

The audit committeeAudit Committee assists our boardBoard of directorsDirectors in overseeing and monitoring the integrity of our financial reporting process, compliance with legal and regulatory requirements and the quality of internal and external audit processes. This committee’s role and responsibilities are set forth in our charter adopted by our boardBoard of directors,Directors, which is available on the Corporate Governance section of our website at www.dbv-technologies.com.https://www.dbv-technologies.com. This committee reviews and reassesses our charter annually and recommends any changes to our boardBoard of directorsDirectors for approval. The audit committeeAudit Committee is responsible for overseeing our overall financial reporting process, and for recommending the appointment, compensation, retention, and oversight of the work of KPMG S.A. and Deloitte & Associés, which is ultimately determined by, respectively, the boardBoard of directorsDirectors or the shareholders. In fulfilling its responsibilities for the DBV Technologies financial statements for the fiscal year ended December 31, 2020,2022, the audit committeeAudit Committee of DBV Technologies took the following actions:

Based on the audit committee’sAudit Committee’s review of the audited financial statements and discussions with management and KPMG S.A. and Deloitte & Associés, the audit committeeAudit Committee recommended to the Company’s boardBoard of directorsDirectors that the audited financial statements be included in the DBV Technologies Annual Report on Form 10-K for the fiscal year ended December 31, 20202022 for filing with the SEC.

Members of the DBV Technologies S.A. Audit Committee

Claire Giraut⁽¹⁾Timothy Morris

Viviane MongesAdora Ndu

Daniel Soland

⁽¹⁾Ms. Giraut resigned from our board of directors and the Audit Committee subsequent to approving the inclusion of audited financial statements in the Annual Report on Form 10-K.Daniele Guyot-Caparros

The material in this report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

Below is a list of our current executive officers and their ages as of April 21, 2021.March 24, 2023. Officers are elected by our boardBoard of directorsDirectors to hold office until their successors are elected and qualified. There is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected.

Sébastien Robitaille has served as our Chief Financial Officer since October 2020. He oversees Finance and Information Systems at the Group level and is a member of the Executive Committee. From July 2019 to October 2020, he served as our Chief of Staff responsible for leading our evolution from a development-stage biotechnology company to a potential commercial organization. From December 2017 to December 2019, he served as our Deputy Chief Financial Officer and oversaw the Finance and Information Systems operations. Mr. Robitaille joined us in September 2015 as Senior Vice President, Group Controller & Information Systems. Prior to joining us, Mr. Robitaille worked at Ipsen, a publicly traded French pharmaceutical company, for 15 years, where he held various roles of increasing. Mr. Robitaille holds a Bachelor’s Degree in Business Administration-Finance from Paris School of Business.

Dr. Pharis Mohideen has served as our Chief Medical Officer since July 2019 and is responsible for continuing development efforts of our pipeline and bringing potentially innovative new treatments to patients, if approved. Dr. Mohideen is a member of our Executive Committee. Prior to joining us, from October 2014 to July 2019, Dr. Mohideen served as Chief Medical Officer for Millendo Therapeutics, Inc., a U.S. publicly traded biopharmaceutical company prior to its merger with Tempest Therapeutics, Inc. From June 2012 to October 2014, he served as Vice President of Clinical Development at Shionogi Inc., a Japanese publicly traded pharmaceutical company. Dr. Mohideen received his M.D., M.S. in human physiology and B.A. in biology from the University of Hawaii, as well as his M.S. in clinical investigation from Vanderbilt University.

Mr. Tassé’s biography is set forth above under “Board Of“Board of Directors and Corporate Governance – Governance—Board Of Directors.of Directors.”

Family Relationships

There are no family relationships among any of our executive officers or directors.

EXECUTIVE COMPENSATION

Summary Compensation Table

The following table sets forth information for each of the last two completed fiscal years regarding compensation awarded to or earned by (i) our Chief Executive Officer (principal executive officer, PEO), and (ii) the two most highly compensated executive officers other than the PEO who were serving as executive officers atfor the end of the last completed fiscal year and (iii) one additional former executive officers who would have been among the two most highly compensated executive officers of the Company other than the PEO had he continued to serve as ofended December 31, 2020,2022, or collectively, the named executive officers.

For the year ended December 31, 2020,2022, our named executive officers were:

Daniel Tassé, our Chief Executive Officer and Director;

Sébastien Robitaille, our Chief Financial Officer; and,

Dr. Pharis Mohideen, our Chief Medical Officer; and

Ramzi Benamar, our former Chief Financial Officer, who left the Company on October 2, 2020.Officer.

Outstanding Equity Awards at Fiscal Year End 20202022